Therapeutic potential of co-signaling receptor modulation in hepatitis B.

Reversing CD8 T cell dysfunction is crucial in treating chronic hepatitis B virus (HBV) infection, yet specific molecular targets remain unclear. Our study analyzed co-signaling receptors during hepatocellular priming and traced the trajectory and fate of dysfunctional HBV-specific CD8 T cells. Early on, these cells upregulate PD-1, CTLA-4, LAG-3, OX40, 4-1BB, and ICOS.

Priming and Maintenance of Adaptive Immunity in the Liver.

The liver's unique characteristics have a profound impact on the priming and maintenance of adaptive immunity. This review delves into the cellular circuits that regulate adaptive immune responses in the liver, with a specific focus on hepatitis B virus infection as an illustrative example. A key aspect highlighted is the liver's specialized role in priming CD8+ T cells, leading to a distinct state of immune hyporesponsiveness.

Interleukin-17 signaling influences CD8 T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells.

IL-17 immune responses in cancer are controversial, with both tumor-promoting and tumor-repressing effects observed. To clarify the role of IL-17 signaling in cancer progression, we used syngeneic tumor models from different tissue origins. We found that deficiencies in host IL-17RA or IL-17A/F expression had varying effects on the growth of different solid tumors including melanoma, sarcoma, lymphoma, and leukemia.

In vitro evaluation of ginsenoside Rg1 immunostimulating effect in bovine mononuclear cells.

The aim of this study was to evaluate the immunomodulatory effect of ginsenoside Rg1 on mammary secretion and peripheral blood mononuclear cells (MSMC and PBMC, respectively). The mRNA expression of TLR2, TLR4 and selected cytokines were evaluated on MSMC after Rg1 treatment. Also, TLR2 and TLR4 protein expression was evaluated on MSMC and PBMC after Rg1 treatment.